Media coverage
7
Media coverage
Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet Morningstar.com Country/Territory United States Date 05/28/20 URL https://www.morningstar.com/news/globe-newswire/7926799/windmil-therapeutics-announces-dosing-of-first-patient-in-phase-2-clinical-study-of-mils-nsclc-in-combination-with-nivolumab-opdivo-for-the-treatment-of-non-small-cell-lung-cancer Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet MarketScreener.com Country/Territory United States Date 05/28/20 URL https://www.marketscreener.com/news/WindMIL-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-2-Clinical-Study-of-MILs-trade-NS--30685906/?utm_medium=RSS&utm_content=20200528 Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet Jotup Country/Territory United States Date 05/28/20 URL https://jotup.co/node/797748 Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet VB Profiles Country/Territory United States Date 05/28/20 URL https://www.vbprofiles.com/press_releases/5ecf9a10b9abe43cc48c8be7 Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs„¢ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 05/28/20 Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet BizWire Express Country/Territory India Date 05/28/20 URL www.bizwireexpress.com/showstoryGNW.php?storyid=12745 Persons Martin Edelman Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ – NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet Global Banking & Finance Review Country/Territory United Kingdom Date 05/27/20 URL https://www.globalbankingandfinance.com/category/news/windmil-therapeutics-announces-dosing-of-first-patient-in-phase-2-clinical-study-of-mils-nsclc-in-combination-with-nivolumab-opdivo-for-the-treatment-of-non-small-cell-lung-cancer/ Persons Martin Edelman